Citigroup Maintains Buy on Evolent Health, Lowers Price Target to $9.5

Evolent Health Inc Class A -1.96%

Evolent Health Inc Class A

EVH

3.51

-1.96%

Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE: EVH) with a Buy and lowers the price target from $11.5 to $9.5.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via